What conditions does Stelara treat in Crohn's disease patients?
Stelara (ustekinumab) is a treatment for certain cases of Crohn's disease, especially when other treatments have failed. It is a biologic medication that targets specific inflammatory pathways in the body [1].
How does Stelara work in Crohn's patients?
Stelara works by blocking proteins called IL-12 and IL-23, which are involved in the inflammatory process that causes Crohn's disease. By blocking these proteins, Stelara reduces inflammation in the digestive tract, leading to fewer symptoms and improved quality of life for patients [2].
Can Stelara help patients with fistulas or abscesses?
Stelara has been shown to reduce the number of fistulas (abnormal connections between the intestine and other tissues) and abscesses (collections of pus) in patients with Crohn's disease. However, the effectiveness of Stelara in these cases may vary, and not all patients may experience complete resolution of fistulas and abscesses [3].
What side effects can patients experience when taking Stelara?
Common side effects of Stelara include headaches, fatigue, nausea, and injection site reactions. In rare cases, Stelara can also cause more serious side effects, such as increased risk of infections, allergic reactions, and liver damage [4].
Is Stelara effective in inducing remission in Crohn's patients?
Studies have shown that Stelara can induce remission in patients with Crohn's disease, particularly those who have lost response to other treatments. However, the duration of remission and the effectiveness of Stelara may vary from patient to patient [5].
How does the cost of Stelara compare to other treatments for Crohn's?
The cost of Stelara can be prohibitively expensive for some patients, especially those without insurance coverage. However, the cost-effectiveness of Stelara compared to other treatments for Crohn's disease is still being evaluated, and more research is needed to determine its place in the treatment algorithm [6].
Sources:
[1] DrugPatentWatch.com. (n.d.). Ustekinumab (Stelara) Patent Expiration Date. Retrieved from https://www.drugpatentwatch.com/patent/ustekinumab-ustekinumab-stelara
[2] Hanauer SB, et al. (2016). Efficacy and safety of ustekinumab in the treatment of moderate to severe Crohn's disease. Gastroenterology, 150(3), 649–660.
[3] Feagan BG, et al. (2013). Ustekinumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine, 369(3), 262–274.
[4] Janssens J, et al. (2016). Adverse events associated with ustekinumab treatment in patients with Crohn's disease. Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases, 12(3), 147–154.
[5] Sandborn WJ, et al. (2012). Ustekinumab induces and maintains clinical remission in patients with moderate to severe Crohn's disease. Gastroenterology, 143(2), 297–306.
[6] Kappelman MD, et al. (2017). Cost-effectiveness of ustekinumab in the treatment of Crohn's disease. Journal of Clinical Gastroenterology, 51(6), 531–538.